Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Stoke Therapeutics (STOK) Equity Average (2022 - 2025)

Stoke Therapeutics (STOK) has 4 years of Equity Average data on record, last reported at $321.5 million in Q3 2025.

  • For Q3 2025, Equity Average rose 35.43% year-over-year to $321.5 million; the TTM value through Sep 2025 reached $321.5 million, up 35.43%, while the annual FY2024 figure was $194.3 million, 12.83% up from the prior year.
  • Equity Average reached $321.5 million in Q3 2025 per STOK's latest filing, down from $342.5 million in the prior quarter.
  • Across five years, Equity Average topped out at $342.5 million in Q2 2025 and bottomed at $150.0 million in Q1 2024.
  • Average Equity Average over 4 years is $225.2 million, with a median of $208.1 million recorded in 2022.
  • Peak YoY movement for Equity Average: decreased 24.77% in 2024, then soared 93.09% in 2025.
  • A 4-year view of Equity Average shows it stood at $194.5 million in 2022, then decreased by 14.51% to $166.3 million in 2023, then soared by 38.66% to $230.6 million in 2024, then surged by 39.45% to $321.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Equity Average were $321.5 million in Q3 2025, $342.5 million in Q2 2025, and $289.5 million in Q1 2025.